NASDAQ Companies

Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful […]

– Industry-leading PK Activator Franchise Has Demonstrated Clinical Efficacy in Four Hematological Diseases, Including New Positive Phase 3 Data in […]

SYRACUSE, N.Y., Jan. 08, 2024 (GLOBE NEWSWIRE) — Carrols Restaurant Group, Inc. (“Carrols” or the “Company”) (Nasdaq: TAST), the largest […]

R1 RCM expects fourth quarter revenue of approximately $563 to $567 million, GAAP Operating income of $36 to $39 million, […]

AUSTIN, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) — Atlas Technical Consultants (Atlas), a leading infrastructure and environmental solutions provider, announced […]

AUSTIN, TX and DURHAM, NC, Jan. 08, 2024 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology […]

–  Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINETMprograms anticipated in 2024 – […]

ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative […]

Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease and expects […]

BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on […]